327 related articles for article (PubMed ID: 28722163)
1. Risk of cancer in patients with psoriasis on biological therapies: a systematic review.
Peleva E; Exton LS; Kelley K; Kleyn CE; Mason KJ; Smith CH
Br J Dermatol; 2018 Jan; 178(1):103-113. PubMed ID: 28722163
[TBL] [Abstract][Full Text] [Related]
2. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
3. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
[TBL] [Abstract][Full Text] [Related]
4. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
5. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
[TBL] [Abstract][Full Text] [Related]
6. Exposure to biological therapies during conception and pregnancy: a systematic review.
Pottinger E; Woolf RT; Exton LS; Burden AD; Nelson-Piercy C; Smith CH
Br J Dermatol; 2018 Jan; 178(1):95-102. PubMed ID: 28718898
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases.
Begon E; Beneton N; Poiraud C; Droitcourt C; Jacobzone C; Vermersch-Langlin A; Descamps V; Perrot JL; Khemis A; Pallure V; Fougerousse AC; Sigal-Grinberg M; Schmutz JL; Goujon C; Reguiai Z;
Br J Dermatol; 2018 Aug; 179(2):512-513. PubMed ID: 29480522
[No Abstract] [Full Text] [Related]
8. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
9. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
10. Adverse Reactions to Biologics in Psoriasis.
Lockwood SJ; Prens LM; Kimball AB
Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
Sorenson E; Koo J
J Dermatolog Treat; 2015; 26(6):493-501. PubMed ID: 25886082
[TBL] [Abstract][Full Text] [Related]
12. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
[TBL] [Abstract][Full Text] [Related]
13. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
14. Antidrug antibodies in psoriasis: a systematic review.
Hsu L; Snodgrass BT; Armstrong AW
Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
[TBL] [Abstract][Full Text] [Related]
15. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
Br J Dermatol; 2015 Nov; 173(5):1183-90. PubMed ID: 26265015
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
[No Abstract] [Full Text] [Related]
17. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
18. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
[TBL] [Abstract][Full Text] [Related]
19. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
